Journal

Health Affairs

ISSN 0278-2715 · Project HOPE

OpenAlex S4210185023

Published here

31 counted works of 31 linked

YearTitleAcademicsSources
2026 Health Services Professionals Endorse Omitting Some Research Information Under Limited Circumstances: Survey Eric M. Patashnik OA GS
2026 Health Services Professionals Endorse Omitting Some Research Information Under Limited Circumstances: Survey: Article examines the views of health service professionals on … Alan S. Gerber GS
2024 Power, Racism, and Health Equity Jamila Michener CV
2023 Racism, Power, and Health Equity: The Case of Tenant Organizing Jamila Michener CV OA GS
2023 The Revolving Door In Health Care Regulation: Study examines revolving door trends of people who move from private industry to the Department of Health and Human Services and … Daniel Paul Carpenter CV GS
2017 Identifying policy levers and opportunities for action across states to achieve health equity Julia Lynch CV OA GS
2016 Liking Health Reform But Turned Off by Toxic Politics Suzanne Mettler CV OA GS
2014 Quantifying The Food and Drug Administration’s Rulemaking Delays Highlights The Need For Transparency Daniel Paul Carpenter CV GS
2010 A National Survey Reveals Public Skepticism About Research-Based Treatment Guidelines Alan S. Gerber; Eric M. Patashnik CV OA GS
2010 Opposition To Guidelines: The Authors Reply Eric M. Patashnik; Alan S. Gerber OA GS
2010 Public Opposition To Guidelines Or Mandatory Treatment?/Opposition To Guidelines: The Authors Reply Alan S. Gerber; Eric M. Patashnik GS
2010 The Political Challenges That May Undermine Health Reform Theda Skocpol CV OA
2010 The Public Wants Information, Not Board Mandates, From Comparative Effectiveness Research Eric M. Patashnik; Alan S. Gerber CV OA GS
2008 Putting Politics First Jacob S. Hacker OA GS
2008 Putting Politics First; Health system reform can be successful this time if policymakers learn the lessons from the past. Jacob S. Hacker GS
2005 A Modest Proposal for Financing Postmarketing Drug Safety Studies by Augmenting FDA User Fees Daniel Paul Carpenter CV GS
2005 A Proposal For Financing Postmarketing Drug Safety Studies By Augmenting FDA User Fees: An incremental policy reform that would enable the FDA and others to exit the current … Daniel Paul Carpenter GS
2005 Using cost-effectiveness analysis to improve health care: Opportunities and barriers Daniel Paul Carpenter GS
2005 What Politics May Be Telling Us about Cost-Effectiveness Analysis Daniel Paul Carpenter CV GS
2004 Drug Safety: The Author Responds Daniel Paul Carpenter GS
2004 The Political Economy of FDA Drug Approval: Processing, Politics and Implications for Policy Daniel Paul Carpenter CV GS
2003 A Polemic for Why Markets Need Cops Daniel Paul Carpenter CV GS
2003 Approval Times for New Drugs: Does the Source of Funding for FDA Staff Matter? Daniel Paul Carpenter CV GS
2003 DECEMBER 2003-PERSPECTIVE: Defending Submission-Year Analyses Of New Drug Approvals Daniel Paul Carpenter GS
2003 Defending Submission-Year Analyses Of New Drug Approvals: A counterargument for why analysis of the year of submission, not the year of approval, is the best way of assessing … Daniel Paul Carpenter GS
2002 Defusing The Alarm Jacob S. Hacker OA GS
1995 Institutional and Political Obstacles to Reform Margaret M. Weir CV OA GS
1995 The Rise and Resounding Demise of the Clinton Plan Theda Skocpol CV OA
1994 Letters: Public Opinion and Reform Robert Y. Shapiro CV OA
1994 Public Opinion and Reform Robert Y. Shapiro CV
1994 Public Opinion's Tilt Against Private Enterprise Robert Y. Shapiro CV OA